Cappel R, Sprecher S, De Cuyper F, De Braekeleer J
J Med Virol. 1985 Jun;16(2):137-45. doi: 10.1002/jmv.1890160206.
A DNA-free herpes simplex type 2 subunit vaccine was administered to 18 volunteers without past evidence of herpes simplex type 1 (HSV 1) or herpes simplex type 2 (HSV 2) infection, to 44 patients with severe recurrent genital HSV 2 infection, and to 15 patients with severe oral type 1 HSV recurrences. The vaccine elicited both humoral and cell-mediated immunity in 97% of the subjects without past HSV infections and boosted significantly the cell-mediated immunity and antibody titers in almost all the patients with recurrent HSV 1 or HSV 2. The vaccine elicited particularly the production of complement-dependent cytotoxic antibodies in 96% of the patients with recurrent HSV 2 infections. This might, at least partly, explain the clinical efficacy of the vaccine. Indeed, we observed a significant decrease (t test, p less than 0.01) in the attack rate of the recurrences and also a significant shortening of the time needed to complete healing of the lesions (t test, p less than 0.01).
一种不含DNA的2型单纯疱疹亚单位疫苗被施用于18名既往无1型单纯疱疹病毒（HSV 1）或2型单纯疱疹病毒（HSV 2）感染证据的志愿者、44名患有严重复发性生殖器HSV 2感染的患者以及15名患有严重复发性1型HSV口腔感染的患者。该疫苗在97%既往无HSV感染的受试者中引发了体液免疫和细胞介导免疫，并在几乎所有复发性HSV 1或HSV 2患者中显著增强了细胞介导免疫和抗体滴度。该疫苗在96%复发性HSV 2感染患者中尤其引发了补体依赖性细胞毒性抗体的产生。这可能至少部分解释了该疫苗的临床疗效。事实上，我们观察到复发率显著降低（t检验，p<0.01），并且病变完全愈合所需时间也显著缩短（t检验，p<0.01）。
